EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 2 November 2017

News

27102017 EFPIA Welcomes Paediatric Medicines Regulation Report and Reiterates its Commitment...
27 October 2017

Entitled: “10 years of the EU Paediatric Regulation,” the report furthermore recognises correctly the continuous commitment... Read more

02112017 EFPIA Statement on the Extension of Activities Concerning EU/US Site Inspections
02 November 2017

The extension of operations is aimed at recognising inspections of manufacturing sites for human medicines conducted... Read more

Blogs

With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcare systems. But developing a new medicine is a long, complex and risky process with no guarantees of success. Over the coming weeks, we look at a number of new medicines and the role that pharmaceutical incentives (or IP) have played in their development.

02112017 Using Incentives as an Innovation Spring-Board to Treat MS
02 November 2017

How incentives helped promote the development of Gilenya Read more

2112017 Incentives, IP and smaller companies; case story: TiGenix
02 November 2017

IP rights and EU pharmaceutical incentives enable innovation for the cures of tomorrow Read more

Events

19 July 2017 War on Cancer – a patient’s journey
21 November 2017 (The HAC, London, UK)

3rd annual conference organised by The Economist Events Read more

14 July 2017 1st European Alliance for Personalised Medicine Congress
27 November 2017 (Belfast, Northern Ireland)

Personalising Your Health: A Global Imperative! Read more

We published

Assessing the impact of proposals for a Supplementary Protection Certificate (SPC) Manufacturing...
27 October 2017 (Publications)

A study by QuintilesIMS Read more

Working together with patient groups
11 October 2017 (Publications)

A publication from the Patient Think Tank to provide guidance for collaboration Read more

Health Collaboration Guide 2017
26 October 2017 (Publications)

Showcasing best practice collaborations between patient organisations and industry, but also local authorities, governments,... Read more

What we are reading

Infographic: What is CAR-T Cell Therapy & How Does it Fight Cancer?
On 18 October 2017 (Labiotech)

Everything you need to know about CAR-T, a revolutionary cell therapy for cancer. Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu